Violari A, Cotton M, Gibb D, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359: 2233-44.
Berk D, Halpern M, Hill D, et al. Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA 2005; 293: 2221-31.
Brady M, Oleske J, Williams P, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART Era. J Acquir Immune Defic Syndr 2010; 53: 86-94.
Sturt A, Halpern M, Sullivan B, Maldonado Y. Timing of Antiretroviral Therapy Initiation and its Impact on Disease Progression in Perinatal Human Immunodeficiency Virus-1 Infection. Pediatr Infect Dis J 2012; 31: 53-60.
Guillén S, San Miguel G, Resino S, et al. Opportunistic infections and organ-specific diseases in HIV-1-infected children: A cohort study (1990-2006). HIV Med 2010; 11: 245-52.
Lindsey J, Malee K, Brouwers P, Hughes M. and the PACTG 219C Study Team. Neurodevelopmental Functioning in HIV-Infected Infants and Young Children Before and After the Introduction of Protease Inhibitor-Based Highly Active Antiretroviral Therapy. PEDIATRICS 2007; 119: e681-93.
Nachman S, Lindsey J, Moye J, et al. Growth of Human Immunodeficiency Virus-Infected Children Receiving Highly Active Antiretroviral Therapy. Pediatr Infect Dis J 2005; 24: 352-7.
Caldwell B, Oxtoby M, Simonds R. 1994 Revised Classification System for Human Immunodeficiency Virus Infection in Children Less Than 13 Years of Age. MMWR 1994; 43: 1-10.
Centers for Disease Control and Prevention. Revised Surveillance Case Definition for HIV Infection--United States, 2014. MMWR 2014; 63: 1-10.
Judd A, Doerholt K, Tookey P, et al. Morbidity, Mortality, and Response to Treatment by Children in the United Kingdom and Ireland with Perinatally Acquired HIV Infection during 1996-2006: Planning for Teenage and Adult Care. Clin Infect Dis 2007; 45: 918-24.
Gortmaker S, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345: 1522-8.
Gibb D, Duong T, Tookey P. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327: 1019-25.
Riersol E. Confluence analysis by means of lag moments and other methods of confluence analysis. Econometrica 1941; 9: 1-24.
Nagelkerke N, Fidler V, Bernsen R. Estimating treatment effects in randomized clinical trials in the presence of non-compliance. Stat Med 2000; 19: 1849-64.
Cuzick J, Edwards R, Segnan N. Adjusting for Non-Compliance and Contamination In Randomized Clinical Trials. Stat Med 1997; 16: 1017-29.
Cole S, Chu H. Effect of acyclovir on herpetic ocular recurrence using a structural nested model. Contemp Clin Trials 2005; 26: 300-10.
Cain L, Cole S, Chmiel J, Margolick J, Rinaldo C, Detels R. Effect of Highly Active Antiretroviral Therapy on Incident AIDS Using Calendar Period as an Instrumental Variable. Am J Epidemiol 2009; 163: 310-5.
Barnett A. Protease Inhibitors Fly Through FDA. Lancet 1996; 347: 678.
Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000; 29: 722-9.
Robins J. Marginal structural models versus structural nested models as tools for causal inference.Statistical Models in Epidemiology: The Environment and Clinical Trials 95-134. Springer-Verlag 1999.
Hernan M, Brumback B, Robins J. Marginal structural models to estimate joint causal effect of nonrandomized treatments. J Am Stat Assoc 2001; 96: 440-8.
Bursac Z, Gauss C, Williams D, Hosmer D. Purposeful selection of variables in logistic regression. Source Code Biol Med 2008; 3(17): 1-8.
Rothman K, Greenland S. Modern Epidemiology. Publisher:
Lippincott-Raven. Philadelphia, PA, 1998.
Dankner WM, Lindsey JC, Levin MJ, et al. CD4 correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J 2001; 20: 40-8.
Gona P, Van Dyke RB, Williams PL, et al. Incidence of Opportunistic and Other Infections in HIV-Infected Children in the HAART Era. JAMA 2006; 296: 292-300.
Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998; 280: 1497.
Miettinen O. The need for randomization in the study of intended effects. Stat Med 1983; 2: 267-71.
Maldonado Y, Wang N, Caldwell B. Factors associated with early clinical recognition of children with perinatal human immunodeficiency virus infection. Northern California Pediatric HIV Consortium. J Infect Dis 1995; 171: 689-92.